Advertisement

Topics

Bristol-Myers Squibb & Sanofi-aventis Company Profile

16:09 EDT 21st September 2018 | BioPortfolio

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY) . For more information, www.sanofi-aventis.us or www.sanofi-aventis.com.


News Articles [1318 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb and Flatiron to collaborate on RWE

Bristol-Myers Squibb and Flatiron have expanded their relationship by announcing a three-year collaboration agreement focused on the use of real...Read More... The post Bristol-Myers Squibb and Flatir...

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combi...

Bristol-Myers Squibb (BMY) Expected to Announce Quarterly Sales of $5.38 Billion

Brokerages forecast that Bristol-Myers Squibb will post $5.38 billion in sales for the current fiscal quarter, according to Zacks Investment Research . Four analysts have made estimates for Bristol-My...

Bristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.10 Billion

Wall Street analysts forecast that Bristol-Myers Squibb will post $5.10 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Bristol-Myers Squibb'...

Bristol-Myers Squibb to Take Part in Barclays Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Global Healthcare Conference on Wednesday, March 14, 2018, in Miami. Murdo Gordon, executive vice presiden...

Bristol-Myers Squibb Announces Departure of Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3...

Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York. Charles Bancroft, executive vice ...

Bristol-Myers Squibb Receives Positive European Agency Opinion

NewsBristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo four-week dosing schedule for advanced melanoma and previously treated renal cell carcinoma.

PubMed Articles [122 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.

To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients w...

THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.

Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous paracetamol has been widely used to treat moderate postoperative pain. Surgery is the main method of treatme...

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.

Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical ...

Review of "Social Media as a Platform for Surgical Learning" by Myers CG, Kudsi OY, Ghaferi AA in Ann Surg 267: 233-235, 2018.

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Companies [191 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

sanofi-aventis/Bristol-Myers Squibb Partnership

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

More Information about "Bristol-Myers Squibb & Sanofi-aventis" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb & Sanofi-aventis news stories on BioPortfolio along with dozens of Bristol-Myers Squibb & Sanofi-aventis Clinical Trials and PubMed Articles about Bristol-Myers Squibb & Sanofi-aventis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb & Sanofi-aventis Companies in our database. You can also find out about relevant Bristol-Myers Squibb & Sanofi-aventis Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record